Effectiveness of a pharmacist-based smoking-cessation program and its impact on quality of life

被引:49
作者
Zillich, AJ
Ryan, M
Adams, A
Yeager, B
Farris, K
机构
[1] Univ Iowa, Coll Pharm, Div Clin & Adm Pharm, Iowa City, IA 52241 USA
[2] Univ Kentucky, Coll Pharm, Div Pharm Practice & Sci, Lexington, KY 40506 USA
[3] Univ Kentucky, Chandler Med Ctr, Dept Pharm, Lexington, KY USA
来源
PHARMACOTHERAPY | 2002年 / 22卷 / 06期
关键词
D O I
10.1592/phco.22.9.759.34073
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
We conducted a prospective, open-label trial to evaluate the effectiveness of a pharmacist-based, comprehensive, smoking-cessation program with 31 self-referred subjects. A secondary goal was to measure changes in health-related quality of life (HRQOL) during the cessation attempt. The program consisted of weekly, 1-hour group sessions over 12 weeks. It incorporated nicotine replacement therapy (patch, gum) with extensive behavior modification counseling. Trained pharmacists served as program facilitators. Smoking cessation was chemically verified at 3 and 6 months by exhaled carbon monoxide. The patients' HRQOL was measured using the smoking-cessation quality of life questionnaire at baseline, 2 weeks, and 1, 2, 3, and 6 months. Chemically verified abstinence rates at 3 and 6 months were 42% (13 patients) and 26% (8 patients), respectively. Among patients who quit, vitality, mental health, and self-control significantly improved during the 3-month program. Six-month cessation rates were modest, although HRQOL improved within 3 months of abstinence.
引用
收藏
页码:759 / 765
页数:7
相关论文
共 39 条
[1]  
ABELIN T, 1989, METHOD FIND EXP CLIN, V11, P205
[2]  
ABELIN T, 1989, LANCET, V1, P7
[3]   PHARMACISTS ROLE IN A SMOKING-CESSATION PROGRAM AT A HEALTH MAINTENANCE ORGANIZATION [J].
BALUCH, WM .
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 1995, 52 (03) :287-293
[4]   COMBINATION OF BEHAVIORAL SMOKING CESSATION WITH TRANSDERMAL NICOTINE SUBSTITUTION [J].
BUCHKREMER, G ;
BENTS, H ;
HORSTMANN, M ;
OPITZ, K ;
TOLLE, R .
ADDICTIVE BEHAVIORS, 1989, 14 (02) :229-238
[5]  
*CDCP, 1993, MMWR-MORBID MORTAL W, V42, P645
[6]  
Centers for Disease Control and Prevention (CDC), 1993, MMWR Morb Mortal Wkly Rep, V42, P504
[7]   NICOTINE REDUCTION THERAPY AND RELAPSE PREVENTION FOR HEAVY SMOKERS - 3-YEAR FOLLOW-UP [J].
COOPER, TM ;
CLAYTON, RR .
JOURNAL OF THE AMERICAN DENTAL ASSOCIATION, 1990, 120 (01) :S32-S36
[8]   STOP-SMOKING PROGRAM USING NICOTINE REDUCTION THERAPY AND BEHAVIOR-MODIFICATION FOR HEAVY SMOKERS [J].
COOPER, TM ;
CLAYTON, RR .
JOURNAL OF THE AMERICAN DENTAL ASSOCIATION, 1989, 118 (01) :47-51
[9]   MEASURING NICOTINE DEPENDENCE - A REVIEW OF THE FAGERSTROM TOLERANCE QUESTIONNAIRE [J].
FAGERSTROM, KO ;
SCHNEIDER, NG .
JOURNAL OF BEHAVIORAL MEDICINE, 1989, 12 (02) :159-182